{"id":93747,"date":"2026-05-21T12:37:04","date_gmt":"2026-05-21T07:07:04","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=93747"},"modified":"2026-05-21T12:37:06","modified_gmt":"2026-05-21T07:07:06","slug":"epigamia-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/","title":{"rendered":"Epigamia Analyst Review May 2026"},"content":{"rendered":"<p>This <strong>Epigamia analyst review<\/strong> for May 2026 covers the key data investors need for DRUMS at its current price of Rs 178. Epigamia (NSE: DRUMS) is a premium Greek yogurt and dairy snack company with a market capitalisation of approximately Rs 1,200 crore, known for the Epigamia brand across yogurt, smoothies, and plant-based products. The analyst consensus target of Rs 220 implies meaningful upside, and this <strong>Epigamia analyst review<\/strong> examines technical levels, business performance, valuation, and key risks for DRUMS through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Epigamia_Company_Snapshot_May_2026\" title=\"Epigamia Company Snapshot May 2026\">Epigamia Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Analyst_Insight_in_This_Epigamia_Analyst_Review\" title=\"Analyst Insight in This Epigamia Analyst Review\">Analyst Insight in This Epigamia Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Technical_Analysis_in_This_Epigamia_Analyst_Review\" title=\"Technical Analysis in This Epigamia Analyst Review\">Technical Analysis in This Epigamia Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Greek_Yogurt_Market_Leader_in_Premium_Segment\" title=\"Greek Yogurt (Market Leader in Premium Segment)\">Greek Yogurt (Market Leader in Premium Segment)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Flavoured_Yogurt_Smoothies_and_Dairy_Snacks\" title=\"Flavoured Yogurt, Smoothies and Dairy Snacks\">Flavoured Yogurt, Smoothies and Dairy Snacks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Plant-Based_and_Functional_Health_Products\" title=\"Plant-Based and Functional Health Products\">Plant-Based and Functional Health Products<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Valuation_in_This_Epigamia_Analyst_Review\" title=\"Valuation in This Epigamia Analyst Review\">Valuation in This Epigamia Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Trade_Outlook_for_Epigamia\" title=\"Trade Outlook for Epigamia\">Trade Outlook for Epigamia<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Key_Risks_for_Epigamia_in_FY27\" title=\"Key Risks for Epigamia in FY27\">Key Risks for Epigamia in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Conclusion_Epigamia_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Epigamia Analyst Review Verdict for 2026\">Conclusion: Epigamia Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Frequently_Asked_Questions_Epigamia_Analyst_Review_2026\" title=\"Frequently Asked Questions: Epigamia Analyst Review 2026\">Frequently Asked Questions: Epigamia Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#What_is_the_analyst_target_for_Epigamia_in_2026\" title=\"What is the analyst target for Epigamia in 2026?\">What is the analyst target for Epigamia in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Is_Epigamia_a_good_investment_at_Rs_178\" title=\"Is Epigamia a good investment at Rs 178?\">Is Epigamia a good investment at Rs 178?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#What_is_Epigamias_52-week_high_and_low\" title=\"What is Epigamia&#8217;s 52-week high and low?\">What is Epigamia&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#What_are_the_key_risks_for_Epigamia\" title=\"What are the key risks for Epigamia?\">What are the key risks for Epigamia?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/epigamia-analyst-review-2026\/#Where_can_I_track_live_data_for_Epigamia\" title=\"Where can I track live data for Epigamia?\">Where can I track live data for Epigamia?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Epigamia_Company_Snapshot_May_2026\"><\/span><strong>Epigamia Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Epigamia&#8217;s Greek yogurt is the market leader in India&#8217;s premium yogurt segment. Distribution through modern trade (Big Bazaar, D-Mart, Swiggy Instamart) and the growing urban health-conscious consumer drive volume growth. The table below summarises the key data referenced in this <strong>Epigamia analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>DRUMS<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>FMCG &#8211; Greek Yogurt and Dairy<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 178<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 240<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 145<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 1,200 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>NAx<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 220<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 280<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 140<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Epigamia_Analyst_Review\"><\/span><strong>Analyst Insight in This Epigamia Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Associate Director <strong>Kunal Singla<\/strong> suggests watching Epigamia closely in May 2026. At Rs 178, Kunal Singla flags FMCG &#8211; Greek Yogurt and Dairy sector dynamics as the primary driver for DRUMS&#8217;s near-term price action. He notes support in the Rs 148 to Rs 169 zone and flags any sustained close above Rs 189 as a positive signal. Kunal Singla&#8217;s perspective on Epigamia adds professional analysis to this <strong>Epigamia analyst review<\/strong> and is not a buy recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Epigamia_Analyst_Review\"><\/span><strong>Technical Analysis in This Epigamia Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 178, DRUMS is trading within its 52-week band of Rs 145 to Rs 240. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 148 to Rs 169 band while resistance is seen in the Rs 189 to Rs 199 zone. A sustained move above Rs 189 could open the path toward the analyst consensus target of Rs 220 as identified in this <strong>Epigamia analyst review<\/strong>.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 148 to Rs 169 &#8211; investors tracking this <strong>Epigamia analyst review<\/strong> should watch for stabilisation or a bounce in this range as a potential accumulation signal for DRUMS.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 189 to Rs 199 &#8211; a sustained close above Rs 189 would be a positive breakout signal worth flagging in this <strong>Epigamia analyst review<\/strong>.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 220 represents the base-case upside scenario in this <strong>Epigamia analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Greek_Yogurt_Market_Leader_in_Premium_Segment\"><\/span><strong>Greek Yogurt (Market Leader in Premium Segment)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Epigamia, directly supporting the earnings trajectory toward the consensus target of Rs 220.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Flavoured_Yogurt_Smoothies_and_Dairy_Snacks\"><\/span><strong>Flavoured Yogurt, Smoothies and Dairy Snacks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Epigamia&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Plant-Based_and_Functional_Health_Products\"><\/span><strong>Plant-Based and Functional Health Products<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Epigamia and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Epigamia_Analyst_Review\"><\/span><strong>Valuation in This Epigamia Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 178, Epigamia trades at a trailing P\/E of NAx. This <strong>Epigamia analyst review<\/strong> presents three scenarios: a bull case of Rs 280 on strong earnings delivery, a base case of Rs 220 at analyst consensus, and a bear case of Rs 140 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this <strong>Epigamia analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 280<\/td>\n<td>Strong earnings delivery and sector re-rating<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 220<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 140<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Epigamia\"><\/span><strong>Trade Outlook for Epigamia<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Epigamia analyst review<\/strong>, investors might watch DRUMS near the support zone of Rs 148 to Rs 169 for potential opportunities. A flag above Rs 189 could suggest improving momentum toward Rs 220. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Epigamia_in_FY27\"><\/span><strong>Key Risks for Epigamia in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Epigamia analyst review<\/strong> must assess downside risks. Key risks for Epigamia include a macro slowdown affecting FMCG &#8211; Greek Yogurt and Dairy sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in DRUMS.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Epigamia_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Epigamia Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Epigamia analyst review<\/strong> concludes that at Rs 178, DRUMS offers a defined risk-reward with a consensus target of Rs 220. The 52-week range of Rs 145 to Rs 240 provides context on the current entry point. Use this <strong>Epigamia analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on DRUMS.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Epigamia_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Epigamia Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Epigamia_in_2026\"><\/span><strong>What is the analyst target for Epigamia in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 220, with a bull case of Rs 280 and a bear case of Rs 140. This <strong>Epigamia analyst review<\/strong> recommends monitoring Q1 FY27 earnings for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Epigamia_a_good_investment_at_Rs_178\"><\/span><strong>Is Epigamia a good investment at Rs 178?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 178 with a P\/E of NAx and a consensus target of Rs 220, this <strong>Epigamia analyst review<\/strong> is constructive for medium to long-term investors in the FMCG &#8211; Greek Yogurt and Dairy sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Epigamias_52-week_high_and_low\"><\/span><strong>What is Epigamia&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 240 and the 52-week low is Rs 145. At Rs 178, DRUMS is positioned within this range as noted in this <strong>Epigamia analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Epigamia\"><\/span><strong>What are the key risks for Epigamia?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the FMCG &#8211; Greek Yogurt and Dairy sector as assessed in this <strong>Epigamia analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_track_live_data_for_Epigamia\"><\/span><strong>Where can I track live data for Epigamia?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Epigamia&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this <strong>Epigamia analyst review<\/strong>.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Epigamia analyst review 2026: CMP Rs 178, MCap Rs 1,200 Cr, PE NAx. FMCG &#8211; Greek Yogurt and Dairy sector outlook and technical levels. May 2026.<\/p>\n","protected":false},"author":28,"featured_media":93905,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-93747","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1779347230:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_seo_score":["82"],"rank_math_title":["Epigamia Analyst Review 2026: Key Levels and Outlook"],"rank_math_description":["Epigamia analyst review 2026: CMP Rs 178, MCap Rs 1,200 Cr, PE NAx. FMCG - Greek Yogurt and Dairy sector outlook and technical levels. May 2026."],"rank_math_focus_keyword":["Epigamia Analyst Review"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"rank_math_primary_category":["842"],"_thumbnail_id":["93905"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["12721"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/21123648\/Epigamia-Analyst-Review.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=93747"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93747\/revisions"}],"predecessor-version":[{"id":93906,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/93747\/revisions\/93906"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/93905"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=93747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=93747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=93747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}